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Few studies have addressed the relationship between generalized anxiety disorder 
(GAD) and cardiovascular prognosis using a diagnostic interview.  
Aim 
To assess the association between GAD and adverse outcomes in myocardial infarction 
(MI) patients. 
Method 
Patients with acute MI (n=438) were recruited between 1997 and 2000 and were 
followed up until 2007. Current GAD and post-MI depression were assessed with the 
Composite International Diagnostic Interview. The endpoint consisted of all-cause 
mortality and cardiovascular related readmissions.  
Results 
During the follow-up period, 198 patients had an adverse event. GAD was associated 
with an increased rate of adverse events after adjustment for age and gender (hazard 
ratio: 1.94; 95% confidence interval: 1.14-3.30; p=0.01). Additional adjustment for 
measures of cardiac disease severity and depression did not change the results.   
Conclusion 
GAD was associated with an almost 2-fold increased risk of adverse outcomes 
independent from demographic and clinical variables and depression.  
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During the last decades, substantial research has focused on the association between 
psychological distress and morbidity and mortality. Most studies have focused on the 
role of depression with coronary heart disease (CHD). Several meta-analyses indicate 
that depression is a risk factor for the development of CHD in the general population (1-
3) and is associated with cardiovascular events and mortality in patients with CHD (3-6).  
 
Less research has focused on the role of anxiety. A recent meta-analysis showed that 
symptoms of anxiety were associated with a 26% increased risk of incident CHD (7). 
Anxiety disorders have been shown to be associated to the development of CHD in a 
younger (8), and to all-cause mortality in an older male population (9). The results for 
generalized anxiety disorder (GAD) are inconsistent. GAD has been shown to be related 
to all-cause mortality in a veteran population (10). However, in a community sample of 
older persons, GAD did not increase the risk of death (11).  
 
In patients with acute myocardial infarction (MI), the prevalence of elevated symptoms of 
anxiety is on average 30% (12). In a meta-analysis including 12 studies covering 5,750 
MI patients, it was shown that anxiety is associated with a 36% increased risk of new 
cardiovascular events or mortality (12). A significant limitation of the studies focusing on 
the relationship between anxiety and impaired prognosis in MI patients conducted this 
far is that most have used questionnaires to assess the presence of elevated symptoms 
of anxiety. Although questionnaires can be used as screening tools (13-16) they are not 
sufficient to diagnose an anxiety disorder. Furthermore, questionnaires are inadequate in 
distinguishing between emotional disorders, specifically between anxiety and depression 
(13,17,18). To our knowledge, only three studies have assessed the association 
between GAD assessed with a diagnostic interview and adverse cardiovascular 
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prognosis. Two of these studies were in patients with (stable) CHD and found significant 
assocations between GAD and cardiovascular events (13,19). In contrast, the third study 
concluded that acute coronary syndrome patients with a lifetime diagnosis of GAD 
tended to experience a better cardiac prognosis (20).   
 
To date no study assessed the prognostic impact of a diagnosis of current GAD after 
acute MI. Therefore, we evaluated the prognostic impact of GAD after MI on new 
cardiovascular events and mortality up till 10 years after the MI using a formal diagnostic 
interview. As GAD and depression are closely associated (21-23) we specifically 




Patients were included from the Depression after Myocardial Infarction (DepreMI) study. 
DepreMI was a naturalistic cohort study evaluating the effects of depression after MI on 
adverse cardiovascular outcomes. Details of this study are described elsewhere (24,25). 
Previous publications on DepreMI have all focused on the association between 
depression and cardiac disease (24-28). These studies found a significant assocation 
between depressive symptoms and incident depressive episodes with cardiovascular 
events after a 2.5 year follow-up period (26-28). The impact of anxiety on cardiovascular 
outcomes has not been examined before. Eligible patients admitted consecutively for MI 
at four hospitals in the Netherlands between September 1997 and September 2000 were 
asked to participate. At least two of the following three criteria for MI had to be met: 1) a 
documented increase in cardiac enzyme levels, 2) typical electrocardiographic changes, 
3) at least 20 minutes of chest pain. Exclusion criteria were the presence of another 
somatic disease likely to influence short-term survival, MI during hospital admission for 
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another reason (except unstable angina), and being unable to participate in study 
procedures. The institutional review board of each participating hospital approved the 
protocol and all participants signed informed consent.  
 
Assessment of GAD 
GAD is characterized by a period of at least six months with prominent tension, worry 
and feelings of apprehension about every day events and problems. Associated 
symptoms are symptoms of autonomic arousal and other somatic or cognitive symptoms 
of tension and worry (29). The presence of an International Classification of Diseases 
(ICD)-10 diagnosis of current GAD was assessed by means of the Composite 
International Diagnostic Interview (CIDI) version 1.1 (30), which was administered 3 





The ICD-10 criteria of GAD 
 
A. A period of at least six months with prominent tension, worry and feelings of 
apprehension, about every-day events and problems. 
B. At least four symptoms out of the following list of items must be present, of which at 
least one from items (1) to (4). 
 
Autonomic arousal symptoms 
 
(1) Palpitations or pounding heart, or accelerated heart rate. 
(2) Sweating. 
(3) Trembling or shaking. 
(4) Dry mouth.  
 
Symptoms concerning chest and abdomen 
 
(5) Difficulty breathing. 
(6) Feeling of choking. 
(7) Chest pain or discomfort. 
(8) Nausea or abdominal distress.  
 
Symptoms concerning brain and mind 
 
(9) Feeling dizzy, unsteady, faint or light-headed. 
(10) Feelings that objects are unreal, or that one's self is distant or "not really here". 
(11) Fear of losing control, going crazy, or passing out. 




(13) Hot flushes or cold chills. 
(14) Numbness or tingling sensations. 
 
Symptoms of tension 
 
(15) Muscle tension or aches and pains. 
(16) Restlessness and inability to relax. 
(17) Feeling keyed up, or on edge, or of mental tension. 
(18) A sensation of a lump in the throat, or difficulty with swallowing. 
 
Other non-specific symptoms 
 
(19) Exaggerated response to minor surprises or being startled. 
(20) Difficulty in concentrating, or mind going blank, because of worrying or anxiety. 
(21) Persistent irritability. 





Assessment of the covariates 
Age, gender, clinical characteristics, cardiac risk factors, and comorbidities were 
assessed during hospitalization for the index-MI and from hospital charts. Left ventricular 
ejection fraction (LVEF) was assessed by echocardiography, radionuclide 
ventriculography, gated single photon emission computed tomography, magnetic 
resonance imaging, angiography or clinical assessment. Living alone and level of 
education were assessed in an interview 3 months after the MI. The presence of an ICD-
10 diagnosis of a post-MI depressive episode was assessed with the CIDI at 3 months 
after the MI.  
 
Assessment of adverse outcomes 
Data concerning mortality were obtained up till 31 December 2007 from the Dutch 
Central Bureau of Statistics by linkage to the municipal personal records database.  
Data concerning hospital admissions in the period between the index-MI and 31 
December 2007 came from the Dutch national registry of hospital discharges and were 
obtained from the Dutch Central Bureau of Statistics by linkage to the municipal personal 
records database. Hospital readmissions with ICD-9 codes 410, 411, 413, 414 (ischemic 
heart disease), 427.1, 427.4, 427.5 (cardiac arrhythmia), 428, 398.91, 402.01, 402.11, 
402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93 (heart failure), 433, 434, 435, 
437.0, 437.1 (cerebrovascular disease) and 440, 443.9 (peripheral vascular disease) 
were included as cardiovascular events. We included these events so to be consistent 
with previous publications on this cohort (26-28). Primary endpoint of this study was a 
combined endpoint of cardiovascular events and all-cause mortality. The follow-up 
period for adverse outcomes started at the CIDI interview at 3 months after the MI and 
ended at 31 December 2007. This timeframe was chosen to optimize the number of 
potential events. Only deaths and cardiovascular related readmissions occurring 
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between the CIDI interview at 3 months after the MI and 31 December 2007 were 
considered as adverse outcomes.  
 
Statistical analyses 
Baseline demographic and clinical characteristics were compared with Chi-square and 
student t-test. For this purpose, non-normally distributed continuous variables were log-
transformed. We calculated event-free survival-time as time to first event or death. If no 
event or death occurred, the patient was censored at 31 December 2007. Using Cox 
regression we evaluated whether event-free survival was different for patients with and 
patients without GAD after the MI. In the basic model, adjustments were made for age 
and gender. Additionally, we adjusted for LVEF, and diagnosis of post-MI depression, 
because these have been shown to be associated with worse cardiovascular prognosis. 
In sensitivity analyses, adjustments were made for other clinical variables that 
significantly predicted cardiovascular events and mortality in the present sample, namely 
anterior site of the index MI, and history of MI and peripheral vascular disease. For all 




For this study, 1,166 patients were assessed for eligibility. Of these, 882 patients were 
eligible of whom 528 (59.9%) signed an informed consent. Of the 461 patients with a 
CIDI interview, 23 were excluded due to missing information on the endpoint, leaving 
438 patients included for further analyses.  
 




Three months after the index MI, 24 patients (5.5%) met the criteria for GAD. Patients 
with GAD were less likely to be treated with percutaneous transluminal coronary 
angioplasty (p=0.03) and more likely to have a history of MI (p=0.02) compared with 
patients without GAD. Of the patients with GAD, 12 (50%) had a concurrent depressive 
episode (table 1).  
INSERT TABLE 1 HERE 
 
During follow-up, 15 (62.5%) patients with GAD had a cardiovascular event or died 
compared with 183 (44.2%) patients without GAD (figure 1).  
 
INSERT FIGURE 1 HERE 
 
Predictors of cardiovascular events and mortality 
 
During the follow-up period, 198 patients met the combined endpoint of all-cause 
mortality and cardiovascular events with a mean (standard deviation) follow-up period of 
5.7 (3.1) years. Patients who had an event during the follow-up period were more likely 
to be older (p<.001), living alone (p=0.04), to have an anterior MI, (p=0.02), a LVEF 
lower than 40 (p<.001), and a history of MI (p=0.001), cerebrovascular disease (p=0.01) 
and peripheral vascular disease (p<.001) (table 2).  
 
INSERT TABLE 2 HERE 
 




Table 3 shows the association of GAD with adverse prognosis for different models. GAD 
was associated with cardiovascular events and mortality after adjustment for age and 
gender (figure 2).  
INSERT FIGURE 2 HERE 
 
After additional adjustment for LVEF, GAD remained an independent predictor of 
adverse outcome. LVEF (hazard ratio (HR): 1.58; 95% confidence interval (CI): 1.17-
2.14; p=0.003) and age (HR per year: 1.03; 95% CI: 1.02-1.04, p<.001) were also 
significant predictors in this model. Adjustment for post MI depression did not affect the 
association between GAD and cardiovascular events and mortality. Post-MI depression 
was not a significant predictor of adverse outcome in this model (HR: 1.20 95% CI: 0.80-
1.80, p=0.38). 
INSERT TABLE 3 HERE 
 
 In sensitivity analyses, in addition to age and gender, consecutive adjustment for history 
of MI, history of peripheral vascular disease, and anterior site of the index MI did not 




This study is the first to assess the prognostic impact of  a diagnosis of current GAD 
following MI on cardiovascular events and all-cause mortality up till 10 years. Patients 
with GAD were at an almost two-fold increased risk of adverse prognosis after 
adjustment for age, gender, and several cardiac disease severity parameters. Our 
findings are in concordance with those of other studies that investigated the impact of 
GAD in patients with stable heart disease (13,19). In the present study, adjustment for 
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depression did not influence the association of GAD with adverse prognosis. This is 
consistent with other studies assessing the association between anxiety and 
cardiovascular events independent from depression (19,31).  
 
Potential mechanisms 
Several potential biological mechanisms might explain the association between GAD 
and CHD. For instance, several studies found a relationship between anxiety and 
indicators of autonomic dysfunction in MI patients, including reduced heart variability 
(32) and reduced baroflex cardiac control (33). Anxiety is also associated with increased 
platelet activity (34) and markers of inflammation (35), in otherwise healthy individuals. 
Another mechanism that may explain the association between anxiety and CHD is 
unhealthy behavior, like physical inactivity, an unhealthy diet, and smoking. Anxiety is 
related to an unhealthy lifestyle in individuals at risk of CHD (36). In addition, anxiety 
following MI is associated with lower adherence to various risk-reducing 
recommendations, such as smoking cessation (37,38). However, in a recent study, a 
variety of potential mediating mechanisms, including levels of cortisol and 
norepinephrine, heart rate variability, inflammation, smoking, medication nonadherence, 
and physical inactivity, could not explain the association between GAD and 
cardiovascular events in patients with stable CHD (19). More research is needed to 
identify the mechanisms through which GAD leads to an adverse prognosis.  
 
Strengths and limitations 
Strength of the present study is the use of a standardized diagnostic interview to assess 
the presence of GAD in this sample of patients with acute MI. Other strengths are the 
long follow-up period and the objective and comprehensive assessment of 
cardiovascular related readmissions and mortality, resulting in a sufficient number of 
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events. Limitations of this study are that we did not have information on the duration of 
the current GAD period or information on whether patients were treated for GAD or 
depression. In addition, we could not take the possible development of new GAD or 
depressive episodes during the time frame of the follow-up period into account. Another 
limitation is the relatively small sample size, which limits our ability to adjust for potential 
covariates simultaneously. An additional limitation resulting from the relatively small 
sample size is that we could not assess the impact of the comorbidity of GAD and 
depression. It has been suggested that GAD and depression might interact 
synergistically to affect cardiovascular mortality (10). However, in a study in patients with 
stable CHD, those with comorbid depression and GAD were not at a greater risk of 
cardiovascular events compared with those with only depression or GAD (13). Further, 
another large population study found that comorbid anxiety symptoms reduced mortality 
compared with depressive symptoms alone (39). Therefore, more research to the impact 
of comorbid anxiety and depression on the development and progression of CHD is 
warranted.  
 
In the present study, the association between GAD and adverse prognosis could not be 
explained by several cardiac disease severity parameters, including LVEF and anterior 
site of the index MI. However, it is still possible that the association is confounded by 
disease severity, especially since some symptoms of GAD, such as palpitations and 
chest pain, might also be symptoms of heart disease. Further, patients with GAD might 
worry about their health and be more likely to consult their doctor and be admitted to the 
hospital with cardiac complaints. This might explain part of the association between GAD 
and cardiovascular related hospital readmissions. To minimize this effect, we excluded 
hospital admissions for chest pain only from our analyses. Furthermore,  although 
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analyses on mortality separate from cardiovascular events were underpowered, the HR 
suggested an adverse effect of GAD on mortality alone as well (data not shown). 
 
Clinical implications 
 Although it has not been specifically studied in patients with heart disease, GAD can be 
effectively treated with psychopharmacological treatment, e.g. selective serotonin 
reuptake inhibitors and serotonin norepinephrine reuptake inhibitors, and cognitive 
behavioral therapy (40). Unfortunately, many patients do not receive adequate treatment 
(40). Besides the impact of anxiety on disability and decreased quality of life, clinicians 
should be aware of the finding that GAD is associated with an increased risk of 
cardiovascular events and mortality following MI.   
 
In summary, this study showed that in patients with acute MI, GAD was associated with 
an almost 2 fold increased risk of new cardiovascular events and mortality. This 
association remained significant after adjustment for age, gender, measures of disease 
severity and depression. More research is needed to identify the mechanisms through 
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Title: Adverse outcomes in patients with and without GAD and depression 
Caption: 
Percentage of cardiac events and all-cause mortality in patients with versus without GAD 
and patients with versus without depression 












GAD and cardiac events and all-cause mortality  
Caption:  
The association of GAD after MI with cardiac events and all-cause mortality adjusted for 
age and gender  












Table 1 Comparison of patients with and without GAD* 
 
 
 No GAD (n=414) GAD (n=24) p 
Age, years mean (sd) 60.7 (11.4) 58.3 (10.9) 0.33 
Male gender n (%) 334 (80.7) 20 (83.3) 0.75 
Primary school only n (%) 78 (18.8) 6 (25.0) 0.46 
Living alone n (%) 58 (14.0) 5 (20.8) 0.35 
Current smoking n (%) 194 (51.3) 14 (63.6) 0.26 
LVEF <40 n (%) 97 (23.5) 7 (29.2) 0.53 
Anterior site of MI n (%) 130 (31.4) 8 (33.3) 0.84 
PTCA n (%) 100 (26.3) 1 (4.8) 0.03 
CABG n (%) 12 (3.2) 2 (9.5) 0.12 
Killip class ≥2 n (%) 13 (3.2) 2 (8.3) 0.18 
CPK-mb mean (SD)† 117.8 (122.9) 121.7 (182.2) 0.16 
CPK mean (SD)† 1322.8 (1319.2) 1818.9 (3010.8) 0.48 
History of MI n (%) 53 (12.8) 7 (29.2) 0.02 
History of cerebral 
vascular disease n (%) 
18 (4.3) 1 (4.2) 0.97 
History of peripheral 
vascular disease n (%) 
27 (6.5) 3 (12.5) 0.26 
Family history of 
cardiovascular disease n 
(%) 
155 (37.4) 9 (37.5) 1.00 
Diabetes n (%) 37 (8.9) 4 (16.7) 0.21 





*t-test for continuous variables and Chi-square for dichotomous variables were used 
†Log-transformations of CPK were used for the t-test 
 
CABG= coronary artery bypass graft; CPK= creatinine phosphokinase; GAD= 
generalized anxiety disorder; LVEF= left ventricular ejection fraction; MI= myocardial 















144 (34.8) 7 (29.2) 0.57 
Body mass index (sd) 26.7 (4.0) 26.8 (4.1) 0.92 
Depression n (%) 53 (12.8) 12 (50.0) <.001 
History of depression 
(including post-MI 
depression) (%) 
75 (18.1) 12 (50.0) <.001 
23 
 
Table 2 Comparison of patients with and without an adverse prognosis* 








Age, years mean (sd) 61 (11.4) 58 (10.8) 63 (11.5) <.001 
Male gender n (%) 354 (80.8) 198 (82.5) 156 (78.8) 0.33 
Primary school only n (%) 84 (19.2) 42 (17.5) 42 (21.2) 0.33 
Living alone n (%) 63 (14.4) 27 (11.3) 36 (18.2) 0.04 
Current smoking n (%) 208 (52.0) 114 (51.1) 94 (53.1) 0.69 
LVEF <40 n (%) 104 (23.8) 40 (16.7) 64 (32.5) <.001 
Anterior site of MI n (%) 138 (31.5) 64 (26.7) 74 (37.4) 0.02 
PTCA n (%) 101 (25.2) 61 (27.4) 40 (22.5) 0.26 
CABG n (%) 14 (3.5) 10 (4.5) 4 (2.2) 0.23 
Killip class ≥2 n (%) 15 (3.4) 6 (2.5) 9 (4.6) 0.24 
CPK-mb mean (SD)† 118.0 (126.6) 117.9 (132.0) 118.1 
(119.9) 
0.75 







History of MI n (%) 60 (13.7) 21 (8.8) 39 (19.7) 0.001 
History of cerebral vascular 
disease n (%) 
19 (4.3) 5 (2.1) 14 (7.1) 0.01 
History of peripheral vascular 
disease n (%) 
30 (6.8) 7 (2.9) 23 (11.6) <.001 
Family history of 
cardiovascular disease n (%) 
164 (37.4) 89 (37.1) 75 (37.9) 0.86 
24 
 
Diabetes n (%) 41 (9.4) 18 (7.5) 23 (11.6) 0.14 
Hypertension n (%) 121 (27.6) 66 (27.5) 55 (27.8) 0.95 
Hypercholesterolemia n (%) 151 (34.5) 80 (33.3) 71 (35.9) 0.58 
Body mass index (sd) 26.7 (4.0) 26.7 (4.5) 26.7 (3.3) 0.98 
Depression n (%) 65 (14.8) 33 (13.8) 32 (16.2) 0.48 
GAD n (%) 24 (5.5) 9 (3.8) 15 (7.6) 0.08 
* t-test for continuous variables and Chi-square for dichotomous variables were used 
†Log-transformations of CPK were used for the t-test 
 
CABG= coronary artery bypass graft; CPK= creatinine phosphokinase; GAD= 
generalized anxiety disorder; LVEF= left ventricular ejection fraction; MI= myocardial 



























Table 3 Association of GAD with cardiac events and all-cause mortality 
 
Controlling for: 
HR (95% CI) p  
Age, gender 1.94 (1.14-3.30) 0.01 
Age, gender, LVEF 1.92 (1.13-3.28) 0.02 
Age, gender, depression 1.84 (1.06-3.17) 0.03 
Age, gender, history of MI 1.81 (1.06-3.09) 0.03 
Age, gender, history of peripheral vascular 
disease 
1.95 (1.15-3.31) 0.01 
Age, gender, anterior site of index MI 1.89 (1.11-3.22) 0.02 
 
CI= confidence interval; GAD= generalized anxiety disorder; HR: hazard ratio; LVEF= 
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